Merck & Company Inc (MRK)vsSimulations Plus Inc (SLP)
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
SLP
Simulations Plus Inc
$14.17
+1.29%
HEALTHCARE · Cap: $300.46M
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 80624% more annual revenue ($65.01B vs $80.53M). MRK leads profitability with a 28.1% profit margin vs -78.0%. MRK appears more attractively valued with a PEG of 3.36. MRK earns a higher WallStSmart Score of 59/100 (C).
MRK
Buy59
out of 100
Grade: C
SLP
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Margin of Safety
+60.0%
Fair Value
$30.25
Current Price
$14.17
$16.08 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Reasonable price relative to book value
Strong operational efficiency at 23.2%
Earnings expanding 46.7% YoY
Areas to Watch
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Smaller company, higher risk/reward
Expensive relative to growth rate
ROE of -38.8% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bull Case : SLP
The strongest argument for SLP centers on Price/Book, Operating Margin, EPS Growth.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Bear Case : SLP
The primary concerns for SLP are Market Cap, PEG Ratio, Return on Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while SLP is a turnaround play — different risk/reward profiles.
SLP carries more volatility with a beta of 1.19 — expect wider price swings.
SLP is growing revenue faster at 8.3% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 50/100), backed by strong 28.1% margins. SLP offers better value entry with a 60.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Simulations Plus Inc
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
Simulations Plus, Inc. develops drug discovery and development software for mechanistic modeling, simulation, and prediction of molecule properties using artificial intelligence and machine learning technology worldwide. The company is headquartered in Lancaster, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?